FRONT COVER

For adults with moderate to severe **ulcerative colitis** or Crohn's disease when current treatment isn't working well enough or cannot be tolerated.

WHEN YOUR HEAD SAYS ONE THING BUT YOUR GUT SAYS "NOT TODAY"



Ask your doctor about ENTYVIO.



MADE FOR THE GI TRACT MADE FOR REMISSION MADE FOR YOU

ENTYVIO acts specifically in the gastrointestinal (GI) tract to help control damaging inflammation. ENTYVIO is clinically proven to provide long-term relief and remission. Individual results may vary.

Uses of ENTYVIO[®] (vedolizumab):

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis
- moderately to severely active Crohn's disease

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.

DIMENSIONS:

WIDTH: 4" HEIGHT: 9"

FRONT COVER

SPREAD





INSIDE:

Clinical Study Results: Ulcerative Colitis4
ENTYVIO Compared to HUMIRA®* (adalimumab)5
Clinical Study Results: Crohn's Disease6-7
How ENTYVIO Works
Real Patient Experiences10-11
Starting ENTYVIO12-13
Important Safety Information14-15
Support from <i>EntyvioConnect</i> 16-17
Speaking with your Doctor20-25

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.

WHY CONSIDER ENTYVIO?

Here are a few things for you and your doctor to discuss about ENTYVIO:



ENTYVIO is the first and only GI-focused biologic.

Approved for ulcerative colitis and Crohn's disease, ENTYVIO acts specifically where the inflammation occurs—in the gastrointestinal (GI) tract.

See pages 8 and 9 for how it works.



ENTYVIO helped patients achieve both long-term relief and remission.

See pages 4-7 for clinical studies.



ENTYVIO and HUMIRA®* (adalimumab) went head to head in an ulcerative colitis study.

See page 5 for results.

Individual results may vary.

*Humira is a registered trademark of AbbVie Inc. North Chicago, IL. For information related to adalimumab, please see AbbVie.com.

SPREAD DIMENSIONS:

WIDTH: 8" HEIGHT: 9"



ENYTVIO DELIVERS RESULTS FOR PATIENTS WITH ULCERATIVE COLITIS

ENTYVIO helps control GI inflammation that occurs in adults with moderate to severe ulcerative colitis when certain other ulcerative colitis medicines have not worked well enough or cannot be tolerated.

In clinical studies, ENTYVIO was shown to help many patients achieve both symptom relief and remission.

Early Results



47% of patients on ENTYVIO achieved response compared to 26% of patients on placebo at Week 6.

Long-term Remission



4

42% of patients achieved remission compared to 16% of patients on placebo at 1 year.

Individual results may vary.

Ask your doctor if ENTYVIO is right for you.

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.



HOW ENTYVIO COMPARED TO HUMIRA®* (adalimumab) IN PATIENTS WITH ULCERATIVE COLITIS



In a separate head-to-head study, ENTYVIO helped

significantly more patients with moderate to severe ulcerative colitis than Humira®* (adalimumab) achieve remission at 1 year.

31.3% of ENTYVIO patients achieved remission compared to 22.5% of Humira patients at 1 year.

*Humira is a registered trademark of AbbVie, Inc. For information related to adalimumab, please see AbbVie.com.



REMISSION ACHIEVED FOR PATIENTS WITH CROHN'S DISEASE

ENTYVIO helps control GI inflammation that occurs in adults with moderate to severe Crohn's disease when certain other Crohn's disease medicines have not worked well enough or cannot be tolerated.

In clinical studies, ENTYVIO was shown to help many patients achieve remission and without depending on steroids.

Remission Achieved



15% of patients achieved remission as early as Week 6 compared to 7% of patients on placebo.



39% of patients achieved remission at 1 year compared to 22% of patients on placebo.

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.



Visit **ENTYVIO.com/CD** to learn more about ENTYVIO for Crohn's disease

Steroid-free Remission



Twice as many patients with Crohn's disease taking ENTYVIO achieved remission without depending on steroids versus patients on placebo at 1 year.

Individual results may vary.




THE ONLY GI-FOCUSED BIOLOGIC FOR ULCERATIVE COLITIS AND CROHN'S DISEASE

Ulcerative colitis and Crohn's disease are the result of an abnormal immune system response, during which your body mistakes certain food, bacteria, and other materials in the intestine for foreign or invading substances. It then sends white blood cells into the intestines where they create inflammation.

This inflammation is usually temporary, but with ulcerative colitis and Crohn's disease, researchers believe that your immune system doesn't know how to "turn off" once it's on. As a result, chronic inflammation damages the intestine and causes symptoms of ulcerative colitis and Crohn's disease.


ENTYVIO is the first and only biologic that acts specifically where inflammation occurs: in the GI tract.



ENTYVIO has a targeted way of working.

ENTYVIO works by binding to a protein on the GI-directed white blood cells, preventing an excess of white blood cells from entering into the GI tract. This helps to control inflammation and symptoms of ulcerative colitis and Crohn's disease.

Learn more about the science of ENTYVIO at HowENTYVIOWorks.com.



Ask your doctor if ENTYVIO is right for you.

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.

8



WHAT REAL PATIENTS ARE SAYING

Living with moderate to severe ulcerative colitis or Crohn's disease brings its challenges. But for these patients, ENTYVIO has made a significant difference. *Individual results may vary.*



Mamie: Patient with Severe Crohn's Disease

Hear more insights from these patients and others at **ENTYVIO.com/PatientStories.**

"None of my meds helped me with my symptoms for more than a few months. Then I tried ENTYVIO, and now I'm in remission."

"I can't even put into words how it felt when my doctor told me I was in remission."



Sarah: Patient with Severe Ulcerative Colitis

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.



STARTING ENTYVIO

ENTYVIO is administered by a healthcare provider through a needle placed in a vein in your arm (intravenously), either at the healthcare provider's office or at an alternate site of care.

Your healthcare provider will monitor you during and after the ENTYVIO infusion for side effects to see if you have a reaction to the treatment.

TREATMENT SCHEDULE



You will receive ENTYVIO by infusion at Weeks 0, 2, and 6.


Maintenance Doses



EVERY 8 WEEKS

Starting at Week 14, you'll recieve 1 infusion every 8 weeks.

- In the first year, you'll receive 8 doses of ENTYVIO
- After the first year, you'll receive 6 doses each year



Hear real patients talk about what it's like to receive an infusion at ENTYVIO.com/PatientStories

The Infusion Takes About 30 Minutes



If you have questions about the infusion process, speak with your doctor.

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.



Important Safety Information for ENTYVIO

- Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients.
- ENTYVIO may cause serious side effects, including:
- o Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feel like your heart is racing).
- o ENTYVIO may increase your risk of getting a serious infection. Before receiving and during treatment with ENTYVIO, tell your healthcare provider if you think you have an infection or symptoms of an infection, such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, red or painful skin or sores on your body, tiredness, or pain during urination.
- o People with weakened immune systems can get progressive multifocal leukoencephalopathy (PML) (a rare, serious brain infection caused by a virus). Although unlikely while receiving ENTYVIO, a risk of PML cannot be ruled out. PML can result in death or severe disability. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any of the following symptoms: confusion or problems thinking, loss of balance, change in the way you walk or talk, decreased strength or weakness on one side of the body, blurred vision, or loss of vision.
- o Liver problems can happen in people who receive ENTYVIO. Tell your healthcare provider right away if you have any of the following symptoms: tiredness, loss of appetite, pain on the right side of your abdomen, dark urine, or yellowing of the skin and eyes (jaundice).

Important Safety Information for ENTYVIO[®] (vedolizumab) (continued)

- The most common side effects of ENTYVIO include common cold, headache, joint pain, nausea, fever, infections of the nose and throat, tiredness, cough, bronchitis, flu, back pain, rash, itching, sinus infection, throat pain, and pain in extremities. These are not all the possible side effects of ENTYVIO. Call your healthcare provider for medical advice about side effects.
- Before receiving ENTYVIO, tell your healthcare provider about all of your medical conditions, including if you: have or think you may have an infection or have infections that keep coming back; have liver problems; have tuberculosis (TB) or have been in close contact with someone with TB; have recently received or are scheduled to receive a vaccine; or if you are pregnant, breastfeeding, plan to become pregnant, or plan to breastfeed.

Please see accompanying full Prescribing Information, including the Medication Guide, for ENTYVIO in pocket and talk with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Uses of ENTYVIO[®] (vedolizumab)

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis
- moderately to severely active Crohn's disease

EntyvioCONNECT

EXPERT HELP WHEN YOU NEED IT MOST

Living with ulcerative colitis or Crohn's disease is difficult enough. Managing your treatment shouldn't be. Once you and your doctor have made the decision to try ENTYVIO, the caring team of experts at *EntyvioConnect* is available to guide you with resources designed to make your journey as stress-free as possible.

Once you're prescribed ENTYVIO, you're eligible for *EntyvioConnect*.



Personalized Guidance

Our Nurse Educators provide one-on-one guidance, resources, and reassurance to help you get started and stay on track with your treatment as prescribed by your doctor. Nurse Educators do not provide medical advice.




Financial and Insurance Help

Our co-pay and other financial resources may help you save on your out-of-pocket costs. Our experts can help navigate your insurance coverage and any eligibility requirements.

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on pages 14 and 15.





Ongoing Support

You'll have access to helpful resources like medication reminders and educational information to help you along the way.



Get Connected

Call **1-844-ENTYVIO** (1-844-368-9846) or sign up at: **ENTYVIO.com/Connect**.





GET READY FOR YOUR DOCTOR VISIT

The questions below can help get your conversation started as you and your doctor explore potential treatment options for your condition. Fill out this page, and bring it with you to your next appointment.



O Never	Occasionally	O Sometimes	O Often	O Alway:
Acciden	ts			
O Never	Occasionally	O Sometimes	O Often	O Alway:
Constipa	ation			
O Never	Occasionally	O Sometimes	O Often	O Alway:
Straining	g during bowel r	novements		
O Never	Occasionally	O Sometimes	O Often	O Alway
Lack of	energy			
O Never	Occasionally	O Sometimes	O Often	O Alway
Please i	ndicate how ye	ou feel using t	he followin	ig scale:
	0 0 0			
Terrible		Okay		Good
Are you	r current treat	ments workin	g well enou	ıgh?
	C Ye) O No		



QUESTIONS TO ASK YOUR DOCTOR

Here are some examples of questions you may want to ask your doctor as you work together to find the best treatment for your specific needs.


How is a biologic medication different from other medications?

Have there been clinical studies that show how biologic treatment options for ulcerative colitis compare to other treatments?

When can I expect to start feeling better?



What goals should I set for my treatment?



While both ulcerative colitis and Crohn's disease are types of inflammatory bowel disease, the effects of ulcerative colitis are limited to the large intestine, which includes: the rectum, descending colon, transverse colon, and ascending colon.

Unlike Crohn's disease, which can affect all layers of the bowel wall, ulcerative colitis affects only the innermost lining of the colon.

NOTES:

Crohn's disease most commonly affects the end of the small bowel (the ileum) and the beginning of the colon.

Crohn's disease can affect the thickness of the bowel wall in any part of the GI tract and the inflammation it causes can "skip"—leaving normal areas in between patches of diseased intestine.

22

For adults with moderate to severe **ulcerative colitis** or Crohn's disease when current treatment isn't working



ENTYVIO: THE ONLY GI-FOCUSED BIOLOGIC FOR ULCERATIVE COLITIS AND CROHN'S DISEASE



ENTYVIO acts specifically in the gastrointestinal (GI) tract to help control damaging inflammation. It is clinically proven to provide long-term relief and remission.



ENTYVIO is the first and only biologic approved just for ulcerative colitis and Crohn's disease.

Individual results may vary.

Entyvio[®] vedolizumab

MADE FOR THE GI TRACT MADE FOR REMISSION MADE FOR YOU

Please see Important Safety Information on pages 14 and 15.

To learn more about ENTYVIO, call **1-844-ENTYVIO** or go to ENTYVIO.com/SignUp and follow us on social media.





ENTYVIO is a trademark of Millennium Pharmaceuticals, Inc., Takeda registered with the U.S. Patent and Trademark Office, and is used under license by Takeda Pharmaceuticals America, Inc. All other trademarks are the property of their respective owners.

©2020 Takeda Pharmaceuticals U.S.A., Inc. Printed in U.S.A/June 2020

All rights reserved. MAT-USD-VED-19-00496v1.0